UPClytics
Alle Fälle anzeigen

UPC CoA 402/2024

11. Juli 2024·EP3167888 Einheitspatent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Verfahrensdetails
Status
Case Closed
Verfahrensart
Berufung
Kategorie
Hauptberufung
Parteien
Kläger
Vertreter
Beklagte
Vertreter
Division
Court of Appeal
Technologie
  • Chemistry
    Biotechnology · Pharmaceuticals
Sprache
English
Erste Entscheidung
30. Juli 2024
Letzte Entscheidung
19. Juni 2025
EPA-Einspruch
Im Vergleich
Wie lange das Gericht bis zu einer ersten Entscheidung braucht.
Median Tage bis zur ersten Entscheidung
Gesamt-UPC124
Richter Rian KaldenGesperrt
Richter Patricia RombachGesperrt
Richter Ingeborg SimonssonGesperrt

Vor dem UPC: AstraZeneca Group (13 Verfahren)·Samsung Group (57 Verfahren)

Dieser Streit umfasst 6 weitere Verfahren

UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC CFI 40/2025·UPC APP 43786/2024 und 1 weitere

3 weitere Beklagte zum selben oder einem verwandten Patent

UPC CFI 642/2024·UPC CoA 405/2024·UPC CFI 124/2024

Starten Sie die kostenlose Testphase, um die Ausgänge zu sehen.

Weitere Verfahren: Court of Appeal·2024

Entscheidungen
  • 2025-06-19

    Zusammenfassung: Court of Appeal Panel 2 rejected Alexion Pharmaceuticals' application for rehearing (R. 245 RoP) of the earlier Court of Appeal order dismissing Alexion's appeal against the Hamburg Local Division's denial of provisional measures. Alexion had alleged fundamental procedural defects (new claim interpretation standard applied without being heard, and incorrect facts). The Court held that no fundamental procedural defect within the meaning of Art. 81(1)(b) UPCA / R. 247(c) RoP was established. Alexion ordered to bear Samsung's costs of the rehearing proceedings.

    Rechtsfragen anzeigen (4)
    • Rehearing application (Art. 81(1)(b) UPCA, R. 245 RoP)
    • Fundamental procedural defect
    • Right to be heard (Art. 76 UPCA)
    • Paroxysmal nocturnal hemoglobinuria treatment / complement inhibitor
  • 2024-12-20
    Appeal RoP220.1Öffentlich

    Zusammenfassung: The Court of Appeal dismissed Alexion's appeal against the Hamburg Local Division's refusal to grant provisional measures against Samsung Bioepis regarding patent EP 3167888. The Court addressed the interpretation of patent claims containing linguistic errors and the relevance of prosecution history.

    Rechtsfragen anzeigen (5)
    • Provisional measures
    • Patent claim interpretation
    • Linguistic error in patent claim
    • Prosecution history
    • Biosimilar pharmaceutical
  • 2024-07-30

    Zusammenfassung: Procedural order from the Court of Appeal dated 30 July 2024 rejecting Alexion Pharmaceuticals' request for expedition of its appeal against the Hamburg Local Division's dismissal of its preliminary injunction application against Samsung Bioepis NL B.V. The CoA found the circumstances were not sufficiently urgent to outweigh Samsung's interest in the standard 15-day response period, noting that the appeal concerned a purely legal issue was insufficient justification, and that Alexion had not used the full time period available to it.

    Rechtsfragen anzeigen (3)
    • Expedition of appeal under R. 9.3(b) RoP
    • Balancing interests of parties in procedural timelines
    • Equality of arms
DokumenttitelDatumÖffentlich
Headnote-and-Keywords2025-06-19Nicht öffentlich
Outcome of the Order2025-06-19Nicht öffentlich
Decision2025-06-19Öffentlich
Comment on the application for rehearing2025-05-12Nicht öffentlich
Outcome of the Order2025-05-08Nicht öffentlich
Order access to recording of oral hearing2025-05-08Öffentlich
Receipt2025-05-06Nicht öffentlich
Request for the recording of the oral hearing to be made available2025-05-06Nicht öffentlich
Headnote-and-Keywords2025-03-18Nicht öffentlich
request comments2025-03-11Nicht öffentlich